Peripheral Primitive Neuroectodermal Tumor

Watchlist

(log in to enable)

Retrieved

2021-01-23

Source

Orphanet

Trials

—

Genes

FLI1, KIT, EWSR1, ERG, CD99, FLII, TP53, ENO2, CHGA, VIM, CCND1, MGMT, C17orf97, SMS, SMARCB1, VHL, EGFR, GFAP, MYC, B2M, PAX3, CDKN2A, ABCB1, KRT20, PIK3CG, SS18, SSTR2, PDGFRA, SNAI2, S100B

FLI1, KIT, EWSR1, ERG, CD99, FLII, TP53, ENO2, CHGA, VIM, CCND1, MGMT, C17orf97, SMS, SMARCB1, VHL, EGFR, GFAP, MYC, B2M, PAX3, CDKN2A, ABCB1, KRT20, PIK3CG, SS18, SSTR2, PDGFRA, SNAI2, S100B, PIK3CA, POMC, PIK3CB, S100A1, PIK3CD, RPE65, PVT1, PAWR, STK11, PTEN, ABO, SYP, CKAP4, PGP, DLEU7, ADGRF3, PHF5A, STK33, BCOR, BHLHE22, B3GAT1, TBC1D9, CHEK2, TUBB3, SYT1, HDAC5, DCLK1, INA, TP63, ZBTB16, UVRAG, UCHL1, NTRK1, TNF, TH, OPRK1, MRC1, NGFR, CDK9, F3, EZH2, ETV4, ERBB2, EEF1B2P2, DMBT1, DCC, CTNNB1, CHGB, CEACAM5, CDK4, NGF, CDK2, CDH2, CD58, CD34, CD6, BRS3, BRCA2, BCL2, ATRX, ASAH1, FGF2, FLT3, FUS, GAPDH, NF1, NEFL, MYCN, ABCC1, NR0B1, MDM2, LIF, KRT19, ITGA2, IL1B, IGF1, HRAS, HPR, HMMR, NRG1, GRP, GRM1, GLS, GIPR, GH1, GCGR, HOTAIR

Drugs

(-)-trans-3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1yl)-4-(1H-indol-3-yl) pyrrolidine-2, 5-dione, (1-methyl-2-nitro-1H-imidazole-5-yl)methyl N,N'-bis(2-bromoethyl) diamidophosphate, 16-base single-stranded peptide nucleic acid oligonucleotide linked to a 7-amino acid peptide, 18-(p-(, 4-oxo-4H-chromene-2-carboxylic acid (2-(2-4-(2-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-ethyl)-phenyl-2H-tetrazol-5-yl)-4,5-dimethoxy-phenyl)-amide, 7-ethyl-10-hydroxy-camptothecin, Anlotinib, Autologous CD4+ and CD8+ T cells transduced with a lentiviral vector encoding an affinity enhanced T cell receptor specific to MAGE-A4, Autologous CD4+ and CD8+ T cells transduced with lentiviral vector containing an affinity-enhanced T-cell receptor targeting the New York esophageal antigen-1, Brostallicin, Camsirubicin, Crenolanib besylate, Deforolimus, Doxorubicin hydrochloride (liposomal) ( DOXIL ), Doxorubicin(6-maleimidocaproyl)hydrazone, Fenretinide, Fibromun, Genetically modified serotype 5/3 adenovirus coding for granulocyte-macrophage colony-stimulating factor, Human/murine chimeric monoclonal antibody against endoglin, Larotrectinib ( VITRAKVI ), Mammalian target of rapamcyin (mTOR) inhibitor, N-acetylsarcosyl-glycyl-L-valyl-D-allo-isoleucyl-L-threonyl-L-norvalyl-L-isoleucyl-L-arginyl-L-prolyl-N-ethylamide, Olaratumab ( LARTRUVO ), Ombrabulin, Paclitaxel ( TAXOL ), Palifosfamide, Propranolol hydrochloride ( HEMANGEOL ), Sindbis virus envelope pseudotyped lentiviral vector encoding New York oesophageal squamous cell carcinoma-1 protein, Trabectedin ( YONDELIS ), Vinorelbine tartrate, Yttrium (90Y)-DTPA-radiolabelled chimeric monoclonal antibody against frizzled homologue 10

Interested in hearing about new therapies?

A rare, aggressive, malignant, neoplastic disease characterized by a usually ill-defined, solid, multilobulated mass, frequently having necrosis, located on any site of the body (except the central nervous system), composed of small, round, poorly differentiated cells, with or without Homer-Wright rosettes, showing varying degrees of neuroectodermal differentiation. Manifestations are variable depending on location, with osteolytic destruction being common when arising from bone.